Discovery of new GPCR ligands to illuminate new biology.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Nature Chemical Biology

• Publication date

  2017-10-18

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1038/nchembio.2490PMID 29045379PMCID PMC5835362
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Structural insight into allosteric modulation of protease-activated receptor 2

  2017cited by this paper
• Structural basis for the cooperative allosteric activation of the free fatty acid receptor GPR40

  2017cited by this paper
• GPCR Dynamics: Structures in Motion.

  2017cited by this paper
• Allosteric “beta-blocker” isolated from a DNA-encoded small molecule library

  2017cited by this paper
• Intracellular allosteric antagonism of the CCR9 receptor

  2016cited by this paper
• Novel Agonist Bioisosteres and Common Structure-Activity Relationships for The Orphan G Protein-Coupled Receptor GPR139

  2016cited by this paper
• Crystal structures of the M1 and M4 muscarinic acetylcholine receptors

  2016cited by this paper
• Identification and molecular docking studies for novel inverse agonists of SREB, super conserved receptor expressed in brain

  2016cited by this paper
• State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 - Relation to antipsychotic-like drug effects.

  2016cited by this paper
• RETRACTED ARTICLE: Orphan receptor ligand discovery by pickpocketing pharmacological neighbors

  2016cited by this paper
• Structure-based discovery of opioid analgesics with reduced side effects

  2016cited by this paper
• Docking Screens for Novel Ligands Conferring New Biology.

  2016cited by this paper
• Identification of a small-molecule ligand that activates the neuropeptide receptor GPR171 and increases food intake

  2016cited by this paper
• Structure‐Based Virtual Screening for Dopamine D2 Receptor Ligands as Potential Antipsychotics

  2016cited by this paper
• In silico design of novel probes for the atypical opioid receptor MRGPRX2

  2016cited by this paper
• DREADDs for Neuroscientists.

  2016cited by this paper
• Identification of Novel Smoothened Ligands Using Structure-Based Docking

  2016cited by this paper
• Novel Scaffold Identification of mGlu1 Receptor Negative Allosteric Modulators Using a Hierarchical Virtual Screening Approach

  2016cited by this paper
• The conformational signature of arrestin3 predicts its trafficking and signaling functions

  2016cited by this paper
• Integrating structural and mutagenesis data to elucidate GPCR ligand binding.

  2016cited by this paper
• Potentiation of M1 Muscarinic Receptor Reverses Plasticity Deficits and Negative and Cognitive Symptoms in a Schizophrenia Mouse Model

  2016cited by this paper
• Structure of CC Chemokine Receptor 2 with Orthosteric and Allosteric Antagonists

  2016cited by this paper
• PRESTO-TANGO: an open-source resource for interrogation of the druggable human GPCR-ome

  2015cited by this paper
• Discovery of GPCR Ligands by Molecular Docking Screening: Novel Opportunities Provided by Crystal Structures.

  2015cited by this paper
• The Recognition of Identical Ligands by Unrelated Proteins.

  2015cited by this paper
• Regulation of the oncoprotein Smoothened by small molecules.

  2015cited by this paper
• Investigation of the role of βarrestin2 in kappa opioid receptor modulation in a mouse model of pruritus.

  2015cited by this paper
• Distinct profiles of functional discrimination among G proteins determine the actions of G protein–coupled receptors

  2015cited by this paper
• ZINC 15 – Ligand Discovery for Everyone

  2015cited by this paper
• Dynamics and structural determinants of ligand recognition of the 5-HT6 receptor

  2015cited by this paper
• Allosteric ligands for the pharmacologically dark receptors GPR68 and GPR65

  2015cited by this paper
• Lead optimization of the VU0486321 series of mGlu1 PAMs. Part 1: SAR of modifications to the central aryl core.

  2015cited by this paper
• Integrated Approaches for Genome-wide Interrogation of the Druggable Non-olfactory G Protein-coupled Receptor Superfamily*

  2015cited by this paper
• The G Protein–Biased κ-Opioid Receptor Agonist RB-64 Is Analgesic with a Unique Spectrum of Activities In Vivo

  2015cited by this paper
• Identification of G protein-biased agonists that fail to recruit β-arrestin or promote internalization of the D1 dopamine receptor.

  2015cited by this paper
• Target identification for a Hedgehog pathway inhibitor reveals the receptor GPR39.

  2014cited by this paper
• Clozapine Acts as an Agonist at Serotonin 2A Receptors to Counter MK-801-Induced Behaviors through a βArrestin2-Independent Activation of Akt

  2014cited by this paper
• Development of allosteric modulators of GPCRs for treatment of CNS disorders.

  2014cited by this paper
• Novel histamine H4 receptor ligands and their potential therapeutic applications: an update

  2014cited by this paper
• Molecular control of δ-opioid receptor signalling

  2014cited by this paper
• Structural basis for Smoothened receptor modulation and chemoresistance to anticancer drugs

  2014cited by this paper
• Novel designer receptors to probe GPCR signaling and physiology.

  2013cited by this paper
• Structure of the CCR5 Chemokine Receptor–HIV Entry Inhibitor Maraviroc Complex

  2013cited by this paper
• Structure-Based Ligand Discovery Targeting Orthosteric and Allosteric Pockets of Dopamine Receptors

  2013cited by this paper
• Signalling profile differences: paliperidone versus risperidone

  2013cited by this paper
• Discovery of a Novel Selective Kappa-Opioid Receptor Agonist Using Crystal Structure-Based Virtual Screening

  2013cited by this paper
• Structural Features for Functional Selectivity at Serotonin Receptors

  2013cited by this paper
• Muscarinic Receptors as Model Targets and Antitargets for Structure-Based Ligand Discovery

  2013cited by this paper
• A G Protein-Biased Ligand at the μ-Opioid Receptor Is Potently Analgesic with Reduced Gastrointestinal and Respiratory Dysfunction Compared with Morphine

  2013cited by this paper
• Emerging paradigms in GPCR allostery: implications for drug discovery

  2013cited by this paper
• Structure of the human smoothened receptor bound to an antitumour agent

  2013cited by this paper
• Molecular Pharmacology and Ligand Docking Studies Reveal a Single Amino Acid Difference between Mouse and Human Serotonin 5-HT2A Receptors That Impacts Behavioral Translation of Novel 4-Phenyl-2-dimethylaminotetralin Ligands

  2013cited by this paper
• Crystal structure of the μ-opioid receptor bound to a morphinan antagonist

  2012cited by this paper
• Biased signalling and allosteric machines: new vistas and challenges for drug discovery

  2012cited by this paper
• New insights from structural biology into the druggability of G protein-coupled receptors.

  2012cited by this paper
• Automated design of ligands to polypharmacological profiles

  2012cited by this paper
• Structure and Dynamics of the M3 Muscarinic Acetylcholine Receptor

  2012cited by this paper
• Limits of Ligand Selectivity from Docking to Models: In Silico Screening for A1 Adenosine Receptor Antagonists

  2012cited by this paper
• Structure-functional selectivity relationship studies of β-arrestin-biased dopamine D₂ receptor agonists.

  2012cited by this paper
• Structural Basis for Allosteric Regulation of GPCRs by Sodium Ions

  2012cited by this paper
• Ligand Discovery from a Dopamine D3 Receptor Homology Model and Crystal Structure

  2011cited by this paper
• Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor.

  2011cited by this paper
• Antagonist Functional Selectivity: 5-HT2A Serotonin Receptor Antagonists Differentially Regulate 5-HT2A Receptor Protein Level In Vivo

  2011cited by this paper
• Cardiorenal Actions of TRV120027, a Novel ß-Arrestin–Biased Ligand at the Angiotensin II Type I Receptor, in Healthy and Heart Failure Canines: A Novel Therapeutic Strategy for Acute Heart Failure

  2011cited by this paper
• Discovery of β-Arrestin–Biased Dopamine D2 Ligands for Probing Signal Transduction Pathways Essential for Antipsychotic Efficacy

  2011cited by this paper
• Conserved binding mode of human beta2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography.

  2010cited by this paper
• Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists.

  2010cited by this paper
• Chemical lead optimization of a pan G(q) mAChR M(1), M(3), M(5) positive allosteric modulator (PAM) lead. Part I: Development of the first highly selective M(5) PAM.

  2010cited by this paper
• Structure-Based Discovery of A2A Adenosine Receptor Ligands

  2010cited by this paper
• Chemical lead optimization of a pan Gq mAChR M1, M3, M5 positive allosteric modulator (PAM) lead. Part II: development of a potent and highly selective M1 PAM.

  2010cited by this paper
• GDC-0449-a potent inhibitor of the hedgehog pathway.

  2009cited by this paper
• Definition of the G protein-coupled receptor transmembrane bundle binding pocket and calculation of receptor similarities for drug design.

  2009cited by this paper
• Docking for fragment inhibitors of AmpC β-lactamase

  2009cited by this paper
• Smoothened Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in Medulloblastoma

  2009cited by this paper
• Parallel Functional Activity Profiling Reveals Valvulopathogens Are Potent 5-Hydroxytryptamine2B Receptor Agonists: Implications for Drug Safety Assessment

  2009cited by this paper
• Structure-based discovery of β2-adrenergic receptor ligands

  2009cited by this paper
• Quantifying Biogenic Bias in Screening Libraries

  2009cited by this paper
• Molecular docking and ligand specificity in fragment-based inhibitor discovery.

  2009cited by this paper
• An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission.

  2008cited by this paper
• Network pharmacology: the next paradigm in drug discovery.

  2008cited by this paper
• β-Arrestins and Cell Signaling

  2007cited by this paper
• Functional Selectivity and Classical Concepts of Quantitative Pharmacology

  2007cited by this paper
• GPCR Engineering Yields High-Resolution Structural Insights into β2-Adrenergic Receptor Function

  2007cited by this paper
• Structure-based activity prediction for an enzyme of unknown function

  2007cited by this paper
• Relating protein pharmacology by ligand chemistry

  2007cited by this paper
• Beta-arrestins and cell signaling.

  2007cited by this paper
• Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa.

  2007cited by this paper
• Reaching for high-hanging fruit in drug discovery at protein–protein interfaces

  2007cited by this paper
• International Union of Pharmacology. XLVI. G Protein-Coupled Receptor List

  2005cited by this paper
• Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia

  2004cited by this paper
• Ligand-supported homology modeling of g-protein-coupled receptor sites: models sufficient for successful virtual screening.

  2004cited by this paper
• RNA Editing Induces Variation in Desensitization and Trafficking of 5-Hydroxytryptamine 2c Receptor Isoforms*

  2004cited by this paper
• International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on Terms and Symbols in Quantitative Pharmacology

  2003cited by this paper
• Nuclear hormone receptor targeted virtual screening.

  2003cited by this paper
• Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B.

  2002cited by this paper
• Comparison of Receptor Mechanisms and Efficacy Requirements for δ-Agonist-Induced Convulsive Activity and Antinociception in Mice

  2002cited by this paper
• Structure-based discovery of a novel, noncovalent inhibitor of AmpC beta-lactamase.

  2002cited by this paper
• Structure-Based Discovery of a Novel, Noncovalent Inhibitor of AmpC β-Lactamase

  2002cited by this paper
• Subnanomolar Inhibitors from Computer Screening: A Model Study Using Human Carbonic Anhydrase II.

  2001cited by this paper
• The Hedgehog and Wnt signalling pathways in cancer

  2001cited by this paper

• A combined in silico approach to design peptide ligands with increased receptor-subtype selectivity.

  2025cites this paper
• Deciphering molecular determinants of GPBAR1-Gs protein interactions by HDX-MS and cryo-EM

  2025cites this paper
• Conformational Heterogeneity Underlying Divergent Signaling in Class A G Protein-Coupled Receptors.

  2025cites this paper
• Chemical coverage of human biological pathways.

  2024cites this paper
• Conserved perception of host and non-host signals via the a-pheromone receptor Ste3 in Colletotrichum graminicola

  2024cites this paper
• Genome-wide pan-GPCR cell libraries accelerate drug discovery

  2024cites this paper
• Chemical Coverage of the Human Reactome

  2024cites this paper
• Discovery of Protease-Activated Receptor 4 (PAR4)-Tethered Ligand Antagonists Using Ultralarge Virtual Screening

  2024cites this paper
• Exploring structure-based drug discovery of GPCRs beyond the orthosteric binding site

  2024cites this paper
• Targeting Odorant Receptors in Adipose Tissue with Food-Derived Odorants: A Novel Approach to Obesity Treatment

  2024cites this paper
• Activation Dynamics for the Taste Receptor as an Energy Sensor

  2024cites this paper
• The path to the G protein‐coupled receptor structural landscape: Major milestones and future directions

  2024cites this paper
• Illuminating the understudied GPCR-ome.

  2023cites this paper
• Accessible and Generalizable in Vitro Luminescence Assay for Detecting GPCR Activation

  2023cites this paper
• Bringing GPCR Structural Biology to Medical Applications: Insights from Both V2 Vasopressin and Mu-Opioid Receptors

  2023cites this paper
• The adhesion GPCRs CELSR1–3 and LPHN3 engage G proteins via distinct activation mechanisms

  2023cites this paper
• The Application of Artificial Intelligence Accelerates G Protein-Coupled Receptor Ligand Discovery

  2023cites this paper
• Allosteric modulators of solute carrier function: a theoretical framework

  2023cites this paper
• The adhesion GPCRs CELSR1-3 and LPHN3 engage G proteins via distinct activation mechanisms

  2023cites this paper
• Prediction of dynamic allostery for the transmembrane domain of the sweet taste receptor subunit, TAS1R3

  2023cites this paper
• An accessible and generalizable in vitro luminescence assay for detecting GPCR activation

  2023cites this paper
• The Many Faces of G Protein-Coupled Receptor 143, an Atypical Intracellular Receptor

  2022cites this paper
• Class A and C GPCR Dimers in Neurodegenerative Diseases

  2022cites this paper
• Docking is not enough: 17-trifluoromethylphenyl trinor PGF2α is only a very weak ligand of neurokinin-1 receptor.

  2022cites this paper
• Probing the structures of G protein-coupled receptors with mass spectrometry-based techniques

  2022cites this paper
• Drug Discovery Strategies for Inherited Retinal Degenerations

  2022cites this paper
• The neuropeptide galanin adopts an irregular secondary structure.

  2022cites this paper
• Design, Synthesis, and Biological Activity of New CB2 Receptor Ligands: from Orthosteric and Allosteric Modulators to Dualsteric/Bitopic Ligands

  2022cites this paper
• AlphaFold2 versus experimental structures: evaluation on G protein-coupled receptors

  2022cites this paper
• Structure-based Discovery of Conformationally Selective Inhibitors of the Serotonin Transporter

  2022influential citation
• Gene Structure, Expression, and 5-HT2B Receptor Signaling

  2021cites this paper
• Structure‐Guided Design of G‐Protein‐Coupled Receptor Polypharmacology

  2021cites this paper
• Exploring the Allosteric Territory of Protein Function.

  2021cites this paper
• Structure-based design of a chemical probe set for the 5-HT5A serotonin receptor

  2021cites this paper
• Selective Manipulation of G-Protein γ7 Subunit in Mice Provides New Insights into Striatal Control of Motor Behavior

  2021cites this paper
• An Integrated Approach toward NanoBRET Tracers for Analysis of GPCR Ligand Engagement

  2021cites this paper
• Structural studies of phosphorylation-dependent interactions between the V2R receptor and arrestin-2

  2021cites this paper
• Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes–7

  2020cites this paper
• Molecular Basis of Opioid Action: From Structures to New Leads.

  2020cites this paper
• Chronic Methadone Use Alters the CD8+ T Cell Phenotype In Vivo and Modulates Its Responsiveness Ex Vivo to Opioid Receptor and TCR Stimuli

  2020cites this paper
• Allosteric drugs and mutations: chances, challenges, and necessity.

  2020cites this paper
• Structure-based view of the druggable genome.

  2020cites this paper
• Nanobody-enabled monitoring of kappa opioid receptor states

  2020cites this paper
• The Evolving Role of Structural Biology in Drug Discovery

  2020cites this paper
• The Druggable Genome as Seen from the Protein Data Bank

  2020cites this paper
• “TRUPATH, an Open-Source Biosensor Platform for Interrogating the GPCR Transducerome”

  2020cites this paper
• G Protein-Coupled Receptors in the Mammalian Blood-Brain Barrier

  2020cites this paper
• Structural insights into emergent signaling modes of G protein–coupled receptors

  2020cites this paper
• Discovery of Potent and Brain-Penetrant GPR52 Agonist that Suppresses Psychostimulant Behavior.

  2020cites this paper
• Variously substituted 2-oxopyridine derivatives: Extending the structure-activity relationships for allosteric modulation of the cannabinoid CB2 receptor.

  2020cites this paper
• Structure of the dopamine D2 receptor in complex with the antipsychotic drug spiperone

  2020cites this paper
• Psychedelic-inspired drug discovery using an engineered biosensor.

  2020cites this paper
• JBC review__Sutkeviciute & Vilardaga_JBC:2019:00934R2

  2020cites this paper
• Comprehensive Characterization of Lipid-Guided G Protein-Coupled Receptor Dimerization.

  2020cites this paper
• Interactions between the opioid and serotonin systems in chronic pain : quantitative live cell study by Fluorescence Cross-Correlation Spectroscopy (FCCS)

  2019cites this paper
• Allosteric Modulation of Cannabinoid Receptor 1—Current Challenges and Future Opportunities

  2019cites this paper
• Characteristics of Allosteric Proteins, Sites, and Modulators.

  2019cites this paper
• Discovery of Human Signaling Systems: Pairing Peptides to G Protein-Coupled Receptors

  2019cites this paper
• Prediction of Conformation Specific Thermostabilizing Mutations for Class A GPCRs.

  2019cites this paper
• GPRC5b Modulates Inflammatory Response in Glomerular Diseases via NF-κB Pathway.

  2019cites this paper
• VEGAS as a Platform for Facile Directed Evolution in Mammalian Cells.

  2019cites this paper
• Molecular pharmacology of metabotropic receptors targeted by neuropsychiatric drugs

  2019cites this paper
• Rational design of agonists for bitter taste receptor TAS2R14: from modeling to bench and back

  2019cites this paper
• Chemogenetics defines receptor-mediated functions of short chain free fatty acids

  2019cites this paper
• D2 Dopamine Receptor G Protein-Biased Partial Agonists Based on Cariprazine.

  2019cites this paper
• How structure informs and transforms chemogenetics.

  2019cites this paper
• Ligand‐directed serotonin 5‐HT2C receptor desensitization and sensitization

  2019cites this paper
• New Binding Sites, New Opportunities for GPCR Drug Discovery.

  2019cites this paper
• Common activation mechanism of class A GPCRs

  2019influential citation
• Fungal G-protein-coupled receptors: mediators of pathogenesis and targets for disease control

  2018cites this paper
• Unexplored therapeutic opportunities in the human genome

  2018cites this paper
• Automated discovery of GPCR bioactive ligands.

  2018cites this paper
• The G protein‐coupled receptors deorphanization landscape

  2018cites this paper
• Exploring the free-energy landscape of GPCR activation

  2018cites this paper
• Protein structure and computational drug discovery.

  2018cites this paper
• The Recognition of Unrelated Ligands by Identical Proteins.

  2018cites this paper
• Emerging strategies targeting CB2 cannabinoid receptor: Biased agonism and allosterism.

  2018cites this paper
• Recent Trends and Applications of Molecular Modeling in GPCR–Ligand Recognition and Structure-Based Drug Design

  2018cites this paper
• Machine learning-assisted discovery of GPCR bioactive ligands

  2018cites this paper
• Structural studies and drug discovery of G protein-coupled receptors

  2018cites this paper
• Structural insights into G-protein-coupled receptor allostery

  2018cites this paper
• How the ubiquitous GPCR receptor family selectively activates signalling pathways

  2018cites this paper
• To Bind or Not to Bind: Unravelling GPCR Polypharmacology.

  2018cites this paper
• New Insights into Modes of GPCR Activation.

  2018cites this paper
• A panoramic view on GPCRs: the 1st Berlin Symposium for Interdisciplinary GPCR research

  2018cites this paper
• Optical functionalization of human Class A orphan G-protein-coupled receptors

  2018cites this paper
• The novel μ‐opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception

  2018cites this paper
• Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes-3

  2017cites this paper
• Virtual Screening and Bioactivity Modeling for G Protein-Coupled Receptors

  year unknowncites this paper